|  Help  |  About  |  Contact Us

Publication : NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis.

First Author  Yang C Year  2010
Journal  PLoS One Volume  5
Issue  11 Pages  e15383
PubMed ID  21151480 Mgi Jnum  J:167281
Mgi Id  MGI:4867757 Doi  10.1371/journal.pone.0015383
Citation  Yang C, et al. (2010) NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis. PLoS One 5(11):e15383
abstractText  BACKGROUND: Maintenance of healthy bone requires the balanced activities of osteoclasts (OCs), which resorb bone, and osteoblasts, which build bone. Disproportionate action of OCs is responsible for the bone loss associated with postmenopausal osteoporosis and rheumatoid arthritis. NF-kappaB inducing kinase (NIK) controls activation of the alternative NF-kappaB pathway, a critical pathway for OC differentiation. Under basal conditions, TRAF3-mediated NIK degradation prevents downstream signaling, and disruption of the NIK:TRAF3 interaction stabilizes NIK leading to constitutive activation of the alternative NF-kappaB pathway. METHODOLOGY/PRINCIPAL FINDINGS: Using transgenic mice with OC-lineage expression of NIK lacking its TRAF3 binding domain (NT3), we now find that alternative NF-kappaB activation enhances not only OC differentiation but also OC function. Activating NT3 with either lysozyme M Cre or cathepsinK Cre causes high turnover osteoporosis with increased activity of OCs and osteoblasts. In vitro, NT3-expressing precursors form OCs more quickly and at lower doses of RANKL. When cultured on bone, they exhibit larger actin rings and increased resorptive activity. OC-specific NT3 transgenic mice also have an exaggerated osteolytic response to the serum transfer model of arthritis. CONCLUSIONS: Constitutive activation of NIK drives enhanced osteoclastogenesis and bone resorption, both in basal conditions and in response to inflammatory stimuli.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

10 Bio Entities

Trail: Publication

0 Expression